Long-Term Safety from the Raltegravir Clinical Development Program

BACKGROUND: Raltegravir has demonstrated potent and durable efficacy and a favorable safety profile in 3 phase III studies in treatment-naïve and treatment-experienced patients with HIV-1 infection. This manuscript provides a review of the raltegravir safety profile using data from these and other s...

Descripción completa

Detalles Bibliográficos
Autores principales: Teppler, Hedy, Brown, Deborah D, Leavitt, Randi Y, Sklar, Peter, Wan, Hong, Xu, Xia, Lievano, Fabio, Lievano, Heidi P, Christopher Mast, T, Nguyen, Bach-Yen T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers Ltd 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267161/
https://www.ncbi.nlm.nih.gov/pubmed/21198432
http://dx.doi.org/10.2174/157016211794582650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267161/
https://www.ncbi.nlm.nih.gov/pubmed/21198432
http://dx.doi.org/10.2174/157016211794582650

Ejemplares similares